Evolving systemic treatment of urothelial cancer

Poster Session 08

Friday 16 March
12:30 - 14:00

Location: Blue Area, Room 1 (Level 0)

Chairs: A. Necchi, Milan (IT)
P. Patel, Edgbaston, Birmingham (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

86

Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC):

Results from Keynote-052

By: Castellano D. 1, Grivas P. 2, Plimack E. 3, Balar A. 4, O'Donnell P. 5, Bellmunt J. 6, Powles T. 7, Hahn N. 8, De Wit R. 9, Bajorin D. 10, Ellison M.C. 11, Frenkiel T. 11, Keefe S. 12, Vuky J. 13

1 Hospital Universitario 12 de Octubre, Dept. of Oncology, Madrid, Spain, 2 Cleveland Clinic, Dept. of Hematology/Medical Oncology Taussig Cancer Institute, Cleveland, United States of America, 3 Fox Chase Cancer Center, Dept. of Oncology, Philadelphia, United States of America, 4 Perlmutter Cancer Center, NYU Langone Medical Center, Dept. of Oncology, New York, United States of America, 5 The University of Chicago Medical Center, Dept. of Oncology, Chicago, United States of America, 6 Dana-Farber Cancer Institute, Dept. of Medicine, Boston, United States of America, 7 Barts Cancer Institute, Queen Mary University of London, Centre for Experimental Cancer Medicine, London, United Kingdom, 8 Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Dept. of Oncology, Baltimore, United States of America, 9 Erasmus MC Cancer Institute, Dept. of Medical Oncology, Rotterdam, Netherlands, The, 10 Memorial Sloan Kettering Cancer Center, Dept. of Oncology, New York, United States of America, 11 Merck & Co., Inc., Dept. of Medical Oncology, Kenilworth, United States of America, 12 Merck & Co., Inc., Dept. of Medical Oncology, Kenilworth, United States of America, 13 Oregon Health & Science University, Dept. of Oncology, Portland, United States of America

87

Adjuvant immunotherapy after cystectomy for MIBC patients: Lessons learned from the phase II clinical trial ‘Magnolia’


1 Radboud UMC, Dept. of Urology, Nijmegen, Netherlands, The, 2 Hopital Edouard Herriot, Dept. of Urology, Lyon, France, 3 Universitätsklinikum Köln, Dept. of Urology, Cologne, Germany, 4 Hospital Universitario Infanta Sofia, Dept. of Urology, Madrid, Spain, 5 Charles University, Dept. of Urology, Prague, Czech Republic, 6 Saint Petersburg State Pavlov Medical University, Dept. of Urology, St. Petersburg, Russia, 7 University of Medicine and
Immune-desert, immune–excluded and inflamed phenotypes predict survival and adjuvant chemotherapy response in patients with MIBC

By: Zhu Y. , Fu H. , Liu Z. , Zhang J. , Ye D.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma

1Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy,
2Fondazione IRCCS Istituto Nazionale dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy,
3University of Athens, Dept. of Medical Oncology, Athens, Greece,
4University of Southampton, Dept. of Medical Oncology, Southampton, United Kingdom,
5Dana-Farber Cancer Institute, Bladder Cancer Center, Boston, United States of America,
6University of Washington, Dept. of Medical Oncology, Seattle, United States of America,
7Heinrich-Heine-University, Dept. of Urology, Dusseldorf, Germany,
8Karmanos Cancer Institute, Dept. of Medical Oncology, Detroit, United States of America,
9Hospital Foch, Dept. of Medical Oncology, Suresnes, France,
10Centre Hospitalier Universitaire Vaudois, Dept. of Medical Oncology, Lausanne, Switzerland,
11Stanford University School of Medicine, Dept. of Medical Oncology, Stanford, United States of America,
12Princess Margaret Hospital, Dept. of Medical Oncology, Toronto, Canada,
13Fox Chase Cancer Center, Dept. of Medical Oncology, Philadelphia, United States of America,
14Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Section, New York, United States of America,
15Barts Health and the Royal Free NHS Trust, Dept. of Medical Oncology, London, United Kingdom,
16Mount Sinai School of Medicine, Tisch Cancer Institute, Dept. of Medical Oncology, New York, United States of America,
17Dana Farber Cancer Institute, Bladder Cancer Center, Boston, United States of America

Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy

By: Von Landenberg N. 1 , Speed J. 2 , Cole A.P. 3 , Seisen T. 4 , Gild P. 5 , Berg S. 1 , Roghmann F. 1 , Noldus J. 1 , Abdollah F. 6 , Menon M. 6 , Kibel A.S. 2 , Trinh Q-D. 7
1Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany,
2Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery, Boston, United States of America,
3Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery, Boston, United States of America,
Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer

By: Hermans T., Voskuilen C., Deelen M., Mertens L., Horenblas S., Meijer R., Boormans J., Aben K., Van Der Heijden M., Pos F., De Wit R., Beerepoot L., Verhoeven R., Van Rhijn B.

1 Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, Netherlands, The,
2 University Medical Centre Utrecht, Dept. of Urology, Utrecht, Netherlands, The,
3 Erasmus University Medical Center, Dept. of Urology, Rotterdam, Netherlands, The,
4 Netherlands Comprehensive Cancer Organization, Dept. of Research, Utrecht, Netherlands, The,
5 Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Medical Oncology, Amsterdam, Netherlands, The,
6 Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Radiation Oncology, Amsterdam, Netherlands, The,
7 Erasmus University Medical Center, Dept. of Medical Oncology, Rotterdam, Netherlands, The,
8 Elisabeth - Twee Steden Hospital, Dept. of Medical Oncology, Tilburg, Netherlands, The

The prognostic significance of tumour-infiltrating lymphocytes and programmed death ligand 1 expression in patients with squamous cell carcinoma of bladder

By: Chen Y., Cao Y., Yang Y., Yu W., Wu S., Jin J.

1 Peking university first hospital, Dept. of Urology, Beijing, China,
2 Peking University Cancer Hospital and Institute, Dept. of Urology, Beijing, China

Evaluation of the safety and short term pathological effects of tri-modal therapy in patients with bladder cancer: A multicenter prospective trial


Osaka Medical College, Dept. of Urology, Osaka, Japan

Healthcare resource utilization in RANGE: Ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced or metastatic urothelial cancer


1 National and Kapodistrian University of Athens, Dept. of Clinical Therapeutics, Athens, Greece,
2 Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Dept. of Medical Oncology, Amsterdam, Netherlands, The,
3 Erasmus MC Cancer Institute, Dept. of Medical Oncology, Rotterdam, Netherlands, The,
4 Centre Léon Bérard, Dept. of Medical Oncology, Lyon, France,
5 University of Tsukuba, Dept. of Urology, Tsukuba, Japan,
6 Hospital Universitario 12 de Octubre, Dept. of Medical Oncology, Madrid, Spain,
Bladder cancer survival in men using 5-alpha-reductase inhibitors

By: Mäkelä V. 1, Kotsar A. 2, Tammela T. 1, Murtola T. 1
1 Tampere University Hospital, Dept. of Urology, Tampere, Finland, 2 Tarto University Hospital, Dept. of Urology, Tarto, Estonia

Bladder cancer survival in users of HDAC-inhibiting antiepileptic drugs in a population-based cohort study

By: Okas R. 1, Kotsar A. 1, Tammela T. 2, Murtola T. 3
1 Tartu University Hospital, Dept. of Urology, Tartu, Estonia, 2 Tampere University Hospital, Dept. of Urology, Tampere, Finland, 3 University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland

Comparative effectiveness of radiotherapy and radical cystectomy in unfit patients with resectable urinary bladder cancer

By: D’Andrea D. 1, Stangl-Kremser J. 1, Goldner G. 2, Soria F. 1, Grubmüller B. 1, Hermann H. 2, Abufaraj M. 1, Foerster B. 1, Kimura S. 1, Shariat S. 1
1 Medical University of Vienna, Dept. of Urology, Vienna, Austria, 2 Medical University of Vienna, Dept. of Radiotherapy, Vienna, Austria

Risk factors for symptomatic recurrence after radical cystectomy in patients with locally advanced bladder cancer

By: Anan G. 1, Hatakayama S. 1, Fujita N. 1, Iwamura H. 2, Tanaka T. 1, Yamamoto H. 1, Tobisawa Y. 1, Yoneyama T. 3, Yoneyama T. 1, Hashimoto Y. 3, Koie T. 1, Ito H. 4, Yoshikawa K. 5, Kawaguchi T. 6, Sato M. 2, Ohyama C. 1
1 Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2 Tohoku Medical and Pharmaceutical University, Dept. of Urology, Sendai, Japan, 3 Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan, 4 Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, 5 Mutsu General Hospital, Dept. of Urology, Mutsu, Japan, 6 Aomori Prefectural Central Hospital, Dept. of Urology, Aomori, Japan

Summary
P. Patel, Edgbaston, Birmingham (GB)